Skip to main content
SpringerLink
Log in

Hypogonadism in Men With Chronic Renal Failure

  • Chapter
Male Hypogonadism

Part of the book series: Contemporary Endocrinology ((COE))

  • 172 Accesses

Abstract

Chronic renal failure has major detrimental effects on male reproductive function, with renal failure, dialysis, and transplantation influencing all levels of the hypothalamic-pituitary-testicular axis (1,2). Although the nonreproductive clinical features of uremia usually overshadow the impaired sexual function, virilization, and infertility of chronic renal failure, comprehensive medical care requires a knowledgeable and empathetic appreciation of men’s valued, but often unstated, expectations of their reproductive health. This chapter reviews the clinical basis for and role of androgen therapy as an adjunct to standard medical care in chronic renal failure.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Handelsman DJ. Hypothalamic-pituitary gonadal dysfunction in chronic renal failure, dialysis, and renal transplantation. Endocr Rev 1985; 6: 151–182.

    Article  PubMed  CAS  Google Scholar 

  2. Handelsman DJ, Liu PY. Androgen therapy in chronic renal failure. Baillieres Clin Endocrinol Metab 1998; 12: 485–500.

    Article  PubMed  CAS  Google Scholar 

  3. Nieschlag E, Nieschlag S, Behre HM. Lifespan and testosterone. Nature 1993; 366: 215.

    Article  PubMed  CAS  Google Scholar 

  4. Anonymous. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1996; 7: 198–207.

    Google Scholar 

  5. Fung L, Pollock CA, Caterson RJ, et al. Dialysis adequacy and nutrition determine prognosis in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1996; 7: 737–744.

    PubMed  CAS  Google Scholar 

  6. Kopple JD. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 1994; 24: 1002–1009.

    PubMed  CAS  Google Scholar 

  7. Dombros NV, Digenis GE, Soliman G, Oreopoulos DG. Anabolic steroids in the treatment of malnourished CAPD patients: a retrospective study. Peritoneal Dialysis Int 1994; 14: 344–347.

    CAS  Google Scholar 

  8. Navarro JF, Mora-Fernandez C, Rivero A, et al. Androgens for the treatment of anemia in peritoneal dialysis patients. Adv Peritoneal Dialysis 1998; 14: 232–235.

    CAS  Google Scholar 

  9. Gascon A, Belvis JJ, Berisa F, Iglesias E, Estopinan V, Teruel JL. Nandrolone decanoate is a good alternative for the treatment of anemia in elderly male patients on hemodialysis. Geriatr Nephrol Urol 1999; 9: 67–72.

    Article  PubMed  CAS  Google Scholar 

  10. Cianciaruso B, Brunori G, Kopple JD, et al. Cross-sectional comparison of malnutrition in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Kidney Dis 1995; 26: 475–486.

    Article  PubMed  CAS  Google Scholar 

  11. Handelsman DJ. The safety of androgens: prostate and cardiovascular disease. In: Wang C, ed. Male Reproductive Function. Kluwer Academic Publishers, Boston, 1998, pp. 227–237.

    Google Scholar 

  12. Handelsman DJ, Dong Q. Hypothalamo-pituitary gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am 1993; 22: 145–161.

    PubMed  CAS  Google Scholar 

  13. Veldhuis JD, Wilkowski MJ, Zwart AD, et al. Evidence for attenuation of hypothalamic gonadotropin-releasing hormone (GnRH) impulse strength with preservation of GnRH pulse frequency in men with chronic renal failure. J Clin Endocrinol Metab 1993; 76: 648–654.

    Article  PubMed  CAS  Google Scholar 

  14. De Celis R, Pedron-Nuevo N. Male fertility of kidney transplant patients with one to ten years of evolution using a conventional immunosuppressive regimen. Arch Androl 1999; 42: 9–20.

    Article  PubMed  Google Scholar 

  15. Ramirez G, Narvarte J, Bittle PA, Ayers-Chastain C, Dean SE. Cyclosporine-induced alterations in the hypothalamic hypophyseal gonadal axis in transplant patients. Nephron 1991; 58: 27–32.

    Article  PubMed  CAS  Google Scholar 

  16. Jecht E, Klupp E, Heidler R, Huben H, Schwarz W. Investigation of the hormonal axis hypothalamuspituitary-gonads in 20 dialyzed men. Andrologia 1980; 12: 146–155.

    Article  PubMed  CAS  Google Scholar 

  17. Stewart-Bentley M, Gans D, Horton R. Regulation of gonadal function in uremia. Metab Clin Exp 1974; 23: 1065–1072.

    Article  PubMed  CAS  Google Scholar 

  18. Handelsman DJ, Ralec VL, Tiller DJ, Horvath JS, Turtle JR. Testicular function after renal transplantation. Clin Endocrinol 1981; 14: 527–538.

    Article  CAS  Google Scholar 

  19. Holdsworth S, Atkins RC, de Kretser DM. The pituitary-testicular axis in men with chronic renal failure. N Engl J Med 1977; 296: 1245–1249.

    Article  PubMed  CAS  Google Scholar 

  20. Lim VS, Fang VS. Restoration of plasma testosterone levels in uremic men with clomiphene citrate. J Clin Endocrinol Metab 1976; 43: 1370–1377.

    Article  PubMed  CAS  Google Scholar 

  21. Dunkel L, Raivio T, Laine J, Holmberg C. Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney Int 1997; 51: 777–784.

    Article  PubMed  CAS  Google Scholar 

  22. Rodger R, Morrison L, Dewar J, Wilkinson R, Ward M, Kerr D. Loss of pulsatile luteinizing hormone secretion in men with chronic renal failure. Br Med J 1985; 291: 1598–1600.

    Article  CAS  Google Scholar 

  23. Wheatley T, Clark P, Raggatt P, Evans D, Holder R. Pulsatility of luteinising hormone in men with chronic renal failure: abnormal rather than absent. Br Med J 1987; 294: 482.

    Article  CAS  Google Scholar 

  24. Talbot JA, Rodger RSC, Robertson WR. Pulsatile bioactive luteinising hormone secretion in men with chronic renal failure and following renal transplantation. Nephron 1990; 56: 66–72.

    Article  PubMed  CAS  Google Scholar 

  25. Schaefer F, Seidel C, Mitchell R, Scharer K, Robertson WR, Cooperative Study Group on Pubertal Development in Chronic Renal Failure (CSPCRF). Pulsatile immunoreactive and bioactive luteinizing hormone secretion in adolescents with chronic renal failure. Pediatr Nephrol 1991; 5: 566–571.

    Article  PubMed  CAS  Google Scholar 

  26. Schaefer F, Veldhuis JD, Robertson WR, Dunger D, Scharer K. Immunoreactive and bioactive luteinizing hormone in pubertal patients with chronic renal failure. Kidney Int 1994; 45: 1465–1476.

    Article  PubMed  CAS  Google Scholar 

  27. Handelsman DJ, Spaliviero JA, Turtle JR. Bioactive luteinizing hormone in plasma of uraemic men and men with primary testicular damage. Clin Endocrinol 1986; 24: 259–266.

    Article  CAS  Google Scholar 

  28. Mitchell R, Bauerfeld C, Schaefer F, Scharer K, Robertson WR. Less acidic forms of luteinizing hormone are associated with lower testosterone secretion in men on haemodialysis treatment. Clin Endocrinol 1994; 41: 65–73.

    Article  CAS  Google Scholar 

  29. Bundschu HD, Rager K, Heller S, et al. Auswirkungen einer langdaueren exogenen Gonadotropinzufuhr auf die testikulare Insuffizienz bei Dauerdialysepatienten. Klinische Wochenschricht 1976; 54: 1039–1046.

    Article  CAS  Google Scholar 

  30. Canale D, Barsantini S, Minervini R, Fiorentini L, Barsotti G, Menchini-Fabris GF. Human chorionic gonadotropin treatment of male sexual inadequacy in patients affected by chronic renal failure. J Androl 1984; 5: 120–124.

    Google Scholar 

  31. Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomised clinical trial of recombinant human chorionic gonadotropin (r-hCG) on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2002; 87: 3125–3135.

    Article  PubMed  CAS  Google Scholar 

  32. Martin-Malo A, Benito P, Castillo D, et al. Effect of clomiphene citrate on hormonal profile in male hemodialysis and kidney transplant patients. Nephron 1993; 63: 390–394.

    Article  PubMed  CAS  Google Scholar 

  33. Sharpe RM. Do males rely on female hormones? Nature 1997; 390: 447–448.

    Article  PubMed  CAS  Google Scholar 

  34. van Coevorden A, Stolear JC, Dhaene M, Herweghem JLv, Mockel J. Effect of chronic oral testosterone undecanoate administration on the pituitary-testicular axes of hemodialyzed male patients. Clin Nephrol 1986; 26: 48–54.

    Google Scholar 

  35. Singh AB, Norris K, Modi N, et al. Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab 2001; 86: 2437–2445.

    Article  PubMed  CAS  Google Scholar 

  36. Johansen KL, Mulligan K, Schambelan M. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial [see comments]. JAMA 1999; 281: 1275–1281.

    Article  PubMed  CAS  Google Scholar 

  37. McNair DM, Lorr M, Droppleman LF. EITS manual for the profile of mood states. Educational and Industrial Testing Service, San Diego, 1971.

    Google Scholar 

  38. Segarra A, Chacon P, Vilardell M, Piera LL. Prospective case-control study to determine the effects of lovastatin on serum testosterone and cortisol concentrations in hyperlipidemic nephrotic patients with chronic renal failure. Nephron 1996; 73: 186–190.

    Article  PubMed  CAS  Google Scholar 

  39. Zofkova I, Sotornik I, Kancheva RL. Adenohypophyseal-gonadal dysfunction in male haemodialyzed patients before and after subtotal parathyroidectomy. Nephron 1996; 74: 536–540.

    Article  PubMed  CAS  Google Scholar 

  40. Kopera H. Miscellaneous uses of anabolic steroids. In: Kochakian CD, ed. Anabolic-Androgenic Steroids. Vol. 43. Springer-Verlag, Berlin, 1976, pp. 535–625.

    Chapter  Google Scholar 

  41. Kruskemper HL. Anabolic Steroids. Academic, New York, 1968, pp. 236.

    Google Scholar 

  42. Dontas AS, Papanicolaou NT, Papanayiotou P, Malamos BK. Long-term effects of anabolic steroids on renal functions in the aged subject. J Gerontol 1967; 22: 268–273.

    Article  PubMed  CAS  Google Scholar 

  43. Wilkey JL, Barson LJ, Kest L, Bragagni A. The effect of testosterone on the azotemic patient: an intermediary report. J Urol 1960; 83: 25–29.

    PubMed  CAS  Google Scholar 

  44. Antus B, Yao Y, Liu S, Song E, Lutz J, Heemann U. Contribution of androgens to chronic allograft nephropathy is mediated by dihydrotestosterone. Kidney Int 2001; 60: 1955–1963.

    Article  PubMed  CAS  Google Scholar 

  45. Muller V, Szabo A, Viklicky O, et al. Sex hormones and gender-related differences: their influence on chronic renal allograft rejection. Kidney Int 1999; 55: 2011–2020.

    Article  PubMed  CAS  Google Scholar 

  46. Loh KC, Salisbury SR, Accott P, Gillis R, Crocker JF. Central precocious puberty and chronic renal failure: a reversible condition post renal transplantation. J Pediatr Endocrinol Metab 1997; 10: 539–545.

    Article  PubMed  CAS  Google Scholar 

  47. Kassmann K, Arsan A, Sharer K, Broyer M. Fonction gonadique et activite genitale des malades transplantes renaux de sexe masculin. Annales de Pediatre 1991; 38: 405–406.

    CAS  Google Scholar 

  48. Jones RWA, El Bishti MM, Bloom SR, et al. The effects of anabolic steroids on growth, body composition, and metabolism in boys with chronic renal failure on regular hemodialysis. J Pediatr 1980; 97: 559–566.

    Article  PubMed  CAS  Google Scholar 

  49. Van Steenbergen MW, Wit JM, Donckerwolcke RA. Testosterone esters advance skeletal maturation more than growth in short boys with chronic renal failure and delayed puberty. Eur J Pediatr 1991; 150: 676–680.

    Article  PubMed  Google Scholar 

  50. Rees L, Greene SA, Rigden SPA, Haycock GB, Chantler C, Preece MA. Oxandrolone for delayed puberty in boys taking long-term steroid therapy for renal disease. Pediatr Nephrol 1990; 4: 160–162.

    Article  PubMed  CAS  Google Scholar 

  51. Giusti M, Perfumo F, Verrina E, et al. Delayed puberty in uremia: pituitary-gonadal function during short-term pulsatile luteinizing hormone-releasing hormone administration. J Endocrinol Invest 1992; 15: 709–717.

    PubMed  CAS  Google Scholar 

  52. Winkler L, Offner G, Krull F, Brodehl J. Growth and pubertal development in nephropathic cystinosis. Eur J Pediatr 1993; 152: 244–249.

    Article  PubMed  CAS  Google Scholar 

  53. Chik CL, Friedman A, Merriam GR, Gahl WA. Pituitary-testicular function in nephropathic cystinosis. Ann Intern Med 1993; 119: 568–575.

    Article  PubMed  CAS  Google Scholar 

  54. Kassmann K, Rappaport R, Broyer M. The short-term effect of testosterone on growth in boys on hemodialysis. Clin Nephrol 1992; 37: 148–154.

    PubMed  CAS  Google Scholar 

  55. Steele TE, Wuerth D, Finkelstein S, et al. Sexual experience of the chronic peritoneal dialysis patient. J Am Soc Nephrol 1996; 7: 1165–1168.

    PubMed  CAS  Google Scholar 

  56. Lawrence IG, Price DE, Howlett TA, Harris KP, Feehally J, Walls J. Correcting impotence in the male dialysis patient: experience with testosterone replacement and vacuum tumescence therapy. Am J Kidney Dis 1998; 31: 313–319.

    Article  PubMed  CAS  Google Scholar 

  57. Barton CH, Mirahmadi MK, Vaziri ND. Effects of long-term testosterone administration on pituitary-testicular axis in end-stage renal failure. Nephron 1982; 31: 61–64.

    Article  PubMed  CAS  Google Scholar 

  58. Chopp RT, Mendez R. Sexual function and hormonal abnormalities in uremic men on chronic dialysis and after renal transplantation. Fertil Steril 1978; 29: 661–666.

    PubMed  CAS  Google Scholar 

  59. Brook AC, Ward MK, Cook DB, Johnston DG, Watson MJ, Kerr DNS. Absence of a therapeutic effect of zinc in the sexual dysfunction of haemodialysis patients. Lancet 1980; 2: 618–620.

    Article  PubMed  CAS  Google Scholar 

  60. Bommer J, del Pozo E, Ritz E, Bommer G. Improved sexual function in male haemodialysis patients on bromocryptine. Lancet 1979; 2: 496–497.

    Article  PubMed  CAS  Google Scholar 

  61. Zetin M, Frost NR, Brumfield D, Stone RA. Amitryptiline stimulates weight gain in hemodialysis patients. Clin Nephrol 1982; 18: 79–82.

    PubMed  CAS  Google Scholar 

  62. Yeksan M, Polat M, Turk S, et al. Effect of vitamin E therapy on sexual functions or uremic patients in hemodialysis. Int J Art Organs 1992; 15: 648–652.

    CAS  Google Scholar 

  63. Yeksan M, Tamer N, Cirit M, et al. Effect of recombinant human erythropoietin (r-HuEPO) therapy on plasma FT3, FT4, TSH, FSH, LH, free testosterone and prolactin levels in hemodialysis patients. Int J Art Organs 1992; 5: 585–589.

    Google Scholar 

  64. Lawrence IG, Price DE, Howlett TA, Harris KP, Feehally J, Walls J. Erythropoietin and sexual dysfunction. Nephrol Dialysis Transplant 1997; 12: 741–747.

    Article  CAS  Google Scholar 

  65. Wu SC, Lin SL, Jeng FR. Influence of erythropoietin treatment on gonadotropic hormone levels and sexual function in male uremic patients. Scand J Urol Nephrol 2001; 35: 136–140.

    Article  PubMed  CAS  Google Scholar 

  66. Schaefer RM, Kokot F, Heidland A. Impact of recombinant erythropoietin on sexual function in hemodialysis patients. In: Baldamus CA, Scigalla P, Wieczorek L, Koch KM, eds. Erythropoietin: From Molecular Structure to Clinical Application. Vol. 76. Karger, Basel, 1989, pp. 273–282.

    Google Scholar 

  67. Kokot F, Wiecek A, Grzeszczak W, Klin M. Infleunce of erythropoietin treatment on follitropin and lutropin response to luliberin and plasma testosterone in haemodialysed patients. Nephron 1990; 56: 126–129.

    Article  PubMed  CAS  Google Scholar 

  68. Diez JJ, Iglesias P, Bajo MA, de Alvaro F, Selgas R. Effects of erythropoietin on gonadotropin responses to gonadotropin-releasing hormone in uremic patients. Nephron 1997; 77: 169–175.

    Article  PubMed  CAS  Google Scholar 

  69. Tokgoz B, Utas C, Dogukan A, et al. Effects of long-term erythropoietin therapy on the hypothalamopituitary-testicular axis in male CAPD patients. Perit Dial Int 2001; 21: 448–454.

    PubMed  CAS  Google Scholar 

  70. Palmer BF. Sexual dysfunction in uremia. J Am Soc Nephrol 1999; 10: 1381.

    PubMed  CAS  Google Scholar 

  71. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397–1404.

    Article  PubMed  CAS  Google Scholar 

  72. MacDougall IC, Mahon A, Muir G, Sidhu P. Randomised placebo-controlled study of sildenafil (Viagra) in peritoneal dialysis patients with erectile dysfunction. J Am Soc Nephrol 1999; 10: 318A.

    Google Scholar 

  73. Chen J, Mabjeesh NJ, Greenstein A, Nadu A, Matzkin H. Clinical efficacy of sildenafil in patients on chronic dialysis. J Urology 2001; 165: 819–821.

    Article  CAS  Google Scholar 

  74. Turk S, Karalezli G, Tonbul HZ, et al. Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dialysis Transplant 2001; 16: 1818–1822.

    Article  CAS  Google Scholar 

  75. Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med 1996; 334: 873–877.

    Article  PubMed  CAS  Google Scholar 

  76. Mansi MK, Alkhudair WK, Huraib S. Treatment of erectile dysfunction after kidney transplantation with intracavernosal self-injection of prostaglandin E1. J Urol 1998; 159: 1927–1930.

    Article  PubMed  CAS  Google Scholar 

  77. Rodriguez Antolin A, Morales JM, Andres A, et al. Treatment of erectile impotence in renal transplant patients with intracavernosal vasoactive drugs. Transplant Proc 1992; 24: 105–106.

    Google Scholar 

  78. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group N Engl J Med 1997; 336: 1–7.

    Article  CAS  Google Scholar 

  79. Prem AR, Punekar SV, Kalpana M, Kelkar AR, Acharya VN. Male reproductive function in uraemia: efficacy of haemodialysis and renal transplantation. Br J Urol 1996; 78: 635–638.

    Article  PubMed  CAS  Google Scholar 

  80. Maeda Y, Nakanishi T, Ozawa K, et al. Anabolic steroid-associated hypogonadism in male hemodialysis patients. Clin Nephrol 1989; 32: 198–201.

    PubMed  CAS  Google Scholar 

  81. Neff MS, Goldberg J, Slifkin RF, et al. Anemia in chronic renal failure. Acta Endocrinol 1985; 271 (suppl): 80–86.

    CAS  Google Scholar 

  82. Winearls CG. Historical review of the use of recombinant human erythropoietin in chronic renal failure. Nephrol Dialysis Transplant 1995; 10 (suppl 2): 3–9.

    Article  Google Scholar 

  83. Navarro JF, Mora C. In-depth review: effect of androgens on anemia and malnutrition in renal failure: implications for patients on peritoneal dialysis. Perit Dialysis Int 2001; 21: 14–24.

    CAS  Google Scholar 

  84. Weber JP, Walsh PC, Peters CA, Spivak JL. Effect of reversible androgen deprivation on hemoglobin and serum erythropoietin in men. Am J Hematol 1991; 36: 190–194.

    Article  PubMed  CAS  Google Scholar 

  85. Teruel JL, Cano T, Marcen R, et al. Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy. Nephrol Dialysis Transplant 1997; 12: 1262–1263.

    Article  CAS  Google Scholar 

  86. von Hartitzsch B, Kerr DNS. Response to parenteral iron with and without androgen therapy in patients undergoing regular haemodialysis. Nephron 1976; 17: 430–438.

    Article  Google Scholar 

  87. Teruel JL, Marcen R, Navarro JF, et al. Evolution of serum erythropoietin after androgen administration to hemodialysis patients: a prospective study. Nephron 1995; 70: 282–286.

    Article  PubMed  CAS  Google Scholar 

  88. Chan PCK, Wei DCC, Tam SCF, Chan FL, Yeung WC, Cheng IKP. Post-transplant erythrocytosis: role of erythropoietin and male sex hormones. Nephrol Dialysis Transplant 1992; 7: 137–142.

    CAS  Google Scholar 

  89. Foresta C, Mioni R, Bordon P, Miotto D, Montini G, Varotto A. Erythropoietin stimulates testosterone production in man. J Clin Endocrinol Metab 1994; 78: 753–756.

    Article  PubMed  CAS  Google Scholar 

  90. Hendler ED, Goffinet JA, Ross S, Longnecker RE, Bakovic V. Controlled study of androgen therapy in anemia of patients on maintenance hemodialysis. N Engl J Med 1974; 291: 1046–1051.

    Article  PubMed  CAS  Google Scholar 

  91. Williams JS, Stein JH, Ferris TF. Nandrolone decanoate therapy for patients receiving hemodialysis. A controlled study. Arch Intern Med 1974; 134: 289–292.

    Article  PubMed  CAS  Google Scholar 

  92. Buchwald D, Argyres S, Easterling RE, et al. Effect of nandrolone decanoate on the anemia of chronic hemodialysis patients. Nephron 1977; 18: 232–238.

    Article  PubMed  CAS  Google Scholar 

  93. Bock EL, Fulle HH, Heimpel H, Pribilla W. Die Wirkung von Mesterolon bei Panmyelopathien und renalen Anaemien. Medizinische Klinik 1976; 1: 539–547.

    Google Scholar 

  94. Naik RB, Gibbons AR, Gyde OH, Harris BR, Robinson BH. Androgen trial in renal anaemia. Proc Eur Dialysis Transplant Assoc 1978; 15: 136–143.

    CAS  Google Scholar 

  95. Neff MS, Goldberg J, Slifkin RF, et al. A comparison of androgens for anemia in patients on hemodialysis. N Engl J Med 1981; 304: 871–875.

    Article  PubMed  CAS  Google Scholar 

  96. Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17: 29–33.

    PubMed  CAS  Google Scholar 

  97. Teruel JL, Aguilera A, Marcen R, Antolin JN, Otero GG, Ortuno J. Androgen therapy for anaemia of chronic renal failure. Scand J Urol Nephrol 1996; 30: 403–408.

    Article  PubMed  CAS  Google Scholar 

  98. Teruel JL, Marcen R, Navarro-Antolin J, Aguilera A, Fernandez-Juarez G, Ortuno J. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: a prospective study. J Am Soc Nephrol 1996; 7: 140–144.

    PubMed  CAS  Google Scholar 

  99. Gaughan WJ, Liss KA, Dunn SR, et al. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 1997; 30: 495–500.

    Article  PubMed  CAS  Google Scholar 

  100. Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992; 37: 264–267.

    PubMed  CAS  Google Scholar 

  101. Horl WH. Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrol Dialysis Transplant 1999; 14: 50–60.

    Article  CAS  Google Scholar 

  102. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriat Soc 1995; 43: 899–901.

    PubMed  CAS  Google Scholar 

  103. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J Clin Endocrinol Metab 1997; 82: 3793–3796.

    Article  PubMed  CAS  Google Scholar 

  104. Jockenhovel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 1997; 2: 293–298.

    PubMed  CAS  Google Scholar 

  105. Powe NR, Griffiths RI, Bass EB. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease. J Am Soc Nephrol 1993; 3: 1610–1671.

    Google Scholar 

  106. Grunstein RR, Handelsman DJ, Lawrence SJ, Blackwell C, Caterson ID, Sullivan CE. Hypothalamic dysfunction in sleep apnea: reversal by nasal continuous positive airways pressure. J Clin Endocrinol Metab 1989; 68: 352–358.

    Article  PubMed  CAS  Google Scholar 

  107. Sandblom RE, Matsumoto AM, Scoene RB, et al. Obstructive sleep apnea induced by testosterone administration. N Engl J Med 1983; 308: 508–510.

    Article  PubMed  CAS  Google Scholar 

  108. Millman RP, Kimmel PL, Shore ET, Wasserstein AG. Sleep apnea in hemodialysis patients: the lack of testosterone effect on its pathogenesis. Nephron 1985; 40: 407–410.

    Article  PubMed  CAS  Google Scholar 

  109. Kimmel PL, Miller G, Mendelson WB. Sleep apnea syndrome in chronic renal disease. Am J Med 1989; 86: 308–314.

    Article  PubMed  CAS  Google Scholar 

  110. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 4: 1966–1972.

    Article  Google Scholar 

  111. Liu PY, Yee B, Wishart SM, Yang Q, Grunstein R, Handelsman DJ. The acute effects of high dose testosterone on sleep in ageing men [abstract]. US Endocrine Society, San Francisco, 2002.

    Google Scholar 

  112. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol 1994; 40: 341–349.

    Article  CAS  Google Scholar 

  113. Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol (Oxf) 2001; 54: 437–445.

    Article  CAS  Google Scholar 

  114. Jin B, Turner L, Walters WAW, Handelsman DJ. Androgen or estrogen effects on the human prostate. J Clin Endocrinol Metab 1996; 81: 4290–4295.

    Article  PubMed  CAS  Google Scholar 

  115. Teruel JL, Aguilera A, Avila C, Ortuno J. Effects of androgen therapy on prostatic markers in hemodialyzed patients. Scand J Urol Nephrol 1996; 30: 129–131.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Peter Y. Liu MB BS, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. Handelsman MB BS, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Metabolism and Diabetes, Department of Medicine, University of Louisville, Louisville, KY, USA

    Stephen J. Winters MD (Chief) (Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Liu, P.Y., Handelsman, D.J. (2004). Hypogonadism in Men With Chronic Renal Failure. In: Winters, S.J. (eds) Male Hypogonadism. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-727-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-727-7_12

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-739-6

  • Online ISBN: 978-1-59259-727-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation